New drugs are not enough-drug repositioning in oncology: An update

被引：64
作者：
Armando, Romina Gabriela [1 ]
Gomez, Diego Luis Mengual [1 ]
Gomez, Daniel Eduardo [1 ]
机构：
[1] Natl Univ Quilmes, Sci & Technol Dept, Lab Mol Oncol, Roque Saenz Pena 352,B1876, Bernal, Argentina
来源：
INTERNATIONAL JOURNAL OF ONCOLOGY | 2020年 / 56卷 / 03期
关键词：
drug; repositioning; repurposing; oncology; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HIV PROTEASE INHIBITORS; CANCER STEM-CELLS; PHOSPHODIESTERASE TYPE 5; HUMAN PROSTATE-CANCER; PHASE-II TRIAL; OVEREXPRESSING TISSUE INHIBITOR; MYELOID-LEUKEMIA MECHANISMS; CALCIUM-CHANNEL ANTAGONISTS; ENDOTHELIAL GROWTH-FACTOR;
D O I：
10.3892/ijo.2020.4966
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.
引用
收藏
页码：651 / 684
页数：34
相关论文
共 567 条
  • [1] Prospects for repurposing CNS drugs for cancer treatment
    Abdelaleem, Mohamed
    Ezzat, Hossam
    Osama, Muhammed
    Megahed, Adel
    Alaa, Waleed
    Gaber, Ahmed
    Shafei, Ayman
    Refaat, Alaa
    [J]. ONCOLOGY REVIEWS, 2019, 13 (01) : 37 - 42
  • [2] Aboukameel Amro, 2018, Oncotarget, V9, P35327, DOI 10.18632/oncotarget.26239
  • [3] Estimating the cost of new drug development: Is it really $802 million?
    Adams, CP
    Brantner, VV
    [J]. HEALTH AFFAIRS, 2006, 25 (02) : 420 - 428
  • [4] A pilot trial of itraconazole pharmacokinetics in patients with metastatic breast cancer
    Ademuyiwa, F. O.
    Zhao, Q.
    Perkins, S. M.
    Gebregziabher, N.
    Jones, D. R.
    Vaughn, L. G.
    Sledge, G. W.
    Miller, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer
    Aftab, Blake T.
    Dobromilskaya, Irina
    Liu, Jun O.
    Rudin, Charles M.
    [J]. CANCER RESEARCH, 2011, 71 (21) : 6764 - 6772
  • [6] Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients
    Agerso, H
    Larsen, LS
    Riis, A
    Lövgren, U
    Karlsson, MO
    Senderovitz, T
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) : 352 - 358
  • [7] Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas
    Ahluwalia, Manmeet S.
    Patton, Carol
    Stevens, Glen
    Tekautz, Tanya
    Angelov, Lilyana
    Vogelbaum, Michael A.
    Weil, Robert J.
    Chao, Sam
    Elson, Paul
    Suh, John H.
    Barnett, Gene H.
    Peereboom, David M.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2011, 102 (02) : 317 - 321
  • [8] Chlorpromazine for Psychosis-Induced Aggression or Agitation
    Ahmed, Uzair
    Jones, Hannah
    Adams, Clive E.
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 (05) : 890 - 891
  • [9] Doxycycline is an NF-κB inhibitor that induces apoptotic cell death in malignant T-cells
    Alexander-Savino, Carolina V.
    Hayden, Matthew S.
    Richardson, Christopher
    Zhao, Jiyong
    Poligone, Brian
    [J]. ONCOTARGET, 2016, 7 (46) : 75954 - 75967
  • [10] Antimetastatic effect of desmopressin in a mouse mammary tumor model
    Alonso, DF
    Skilton, G
    Farías, EF
    Joffé, EBD
    Gomez, DE
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1999, 57 (03) : 271 - 275
12345678910